# MD1003-AMN MD1003 in Adrenomyeloneuropathy

> **NCT02961803** · PHASE2,PHASE3 · COMPLETED · sponsor: **MedDay Pharmaceuticals SA** · enrollment: 67 (actual)

## Conditions studied

- Adrenomyeloneuropathy
- Adrenoleukodystrophy
- AMN

## Interventions

- **DRUG:** MD1003 100 mg capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02961803
- **Lead sponsor:** MedDay Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-06
- **Final completion:** 2017-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2017-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961803, "MD1003-AMN MD1003 in Adrenomyeloneuropathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02961803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*